Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 11/20 | 0.63 |
| ▸ | KIT known ✓ | P10721 | 7/20 | 0.63 |
| ▸ | PDGFRA known ✓ | P16234 | 7/20 | 0.63 |
| ▸ | CSF1R known ✓ | P07333 | 4/20 | 0.63 |
| ▸ | FLT1 known ✓ | P17948 | 3/20 | 0.63 |
| ▸ | FLT4 known ✓ | P35916 | 3/20 | 0.63 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.63 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.63 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.63 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.63 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.63 |
| ▸ | MET known ✓ | P08581 | 1/20 | 0.63 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.63 |
| ▸ | FGFR1 known ✓ | P11362 | 1/20 | 0.63 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.63 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.63 |
| ▸ | FGFR3 known ✓ | P22607 | 1/20 | 0.63 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.63 |
| ▸ | ALK known ✓ | Q9UM73 | 1/20 | 0.63 |
| ▸ | HDAC1 known ✓ | Q13547 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL935691 | 0.99 | BTK (0.76) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL724300 | 0.99 | BTK (0.79) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL4427732 | 0.97 | BTK (0.75) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL725543 | 0.92 | BTK (0.67) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL15973689 | 0.88 | BTK (0.62) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL12575010 | 0.88 | BTK (1.00) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL17135511 | 0.85 | BTK (0.58) | BTKKDRKITPDGFRACSF1R | |
| Hydrochloric Acid SCHEMBL6125704 | 0.85 | BTK (0.56) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL29884143 | 0.85 | BTK (0.73) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL28843997 | 0.85 | BTK (0.73) | BTKKDRKITPDGFRACSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240285622-A1 | PAZOPANIB ORAL PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI AURORA BIOTECHNOLOGY CO., LTD. (CN) | 2024-08-29 | — | — | US | claimed |
| EP-4378451-A1 | PAZOPANIB ORAL PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Aurora Biotechnology Co., Ltd. (CN) | 2024-06-05 | — | — | EP | claimed |
| CN-115671110-A | Pazopanib oral pharmaceutical composition, preparation method and application thereof | 上海博志研新药物技术有限公司 | 2023-02-03 | — | — | CN | claimed |
| US-10596263-B2 | Pazopanib formulation | NOVARTIS AG (CH) | 2020-03-24 | — | — | US | claimed |
| US-20180360971-A1 | PAZOPANIB FORMULATION | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2018-12-20 | — | — | US | claimed |
| US-10080802-B2 | Pazopanib formulation | NOVARTIS AG (CH) | 2018-09-25 | — | — | US | claimed |
| US-20170239255-A1 | Combination | NOVARTIS AG (CH) | 2017-08-24 | — | — | US | claimed |
| US-20160120988-A1 | PAZOPANIB FORMULATION | NOVARTIS AG (CH) | 2016-05-05 | — | — | US | claimed |
| US-9278099-B2 | Pazopanib formulation | NOVARTIS AG (CH) | 2016-03-08 | — | — | US | claimed |
| US-20150352117-A1 | COMBINATION | NOVARTIS AG (CH) | 2015-12-10 | — | — | US | claimed |
| EP-2773204-A1 | PAZOPANIB FORMULATION | Glaxo Wellcome Manufacturing Pte Ltd (SG) | 2014-09-10 | — | — | EP | claimed |
| WO-2014085373-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2014-06-05 | — | — | WO | claimed |
| WO-2014066204-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2014-05-01 | — | — | WO | claimed |
| US-20130237554-A1 | COMBINATION | NOVARTIS PHARMA AG (CH) | 2013-09-12 | — | — | US | claimed |
| EP-2608790-A1 | PHARMACEUTICAL COMBINATION OF A VEGFR INHIBITOR AND A MEK INHIBITOR USEFUL FOR TREATING CANCER | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-03 | — | — | EP | claimed |
| US-20130165456-A1 | COMBINATION | NOVARTIS AG (CH) | 2013-06-27 | — | — | US | claimed |
| WO-2013066616-A1 | PAZOPANIB FORMULATION | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2013-05-10 | — | — | WO | claimed |
| EP-2575460-A1 | COMBINATION | GlaxoSmithKline LLC (US) | 2013-04-10 | — | — | EP | claimed |
| WO-2012027438-A1 | PHARMACEUTICAL COMBINATION OF A VEGFR INHIBITOR AND A MEK INHIBITOR USEFUL FOR TREATING CANCER | GLAXOSMITHKLINE LLC (US) | 2012-03-01 | — | — | WO | claimed |
| WO-2011150044-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2011-12-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165456-A1 | COMBINATION | PAICS, CA5A, CA5B | KDR 3825/4885KIT 2555/4885PDGFRA 1607/4885 |
| US-10596263-B2 | Pazopanib formulation | PDGFRB, STAT5B, JAK2 | KDR 10/4885KIT 31/4885PDGFRA 5/4885 |
| US-20150352117-A1 | COMBINATION | PAICS, CA5A, CA5B | KDR 3825/4885KIT 2555/4885PDGFRA 1607/4885 |
| US-20160120988-A1 | PAZOPANIB FORMULATION | PDGFRB, STAT5B, JAK2 | KDR 10/4885KIT 31/4885PDGFRA 5/4885 |
| US-20240285622-A1 | PAZOPANIB ORAL PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, JAK1 | KDR 149/4885KIT 664/4885PDGFRA 734/4885 |
| US-20130237554-A1 | COMBINATION | TPMT, NUP205, MGMT | KDR 3541/4885KIT 2927/4885PDGFRA 2735/4885 |
| US-10080802-B2 | Pazopanib formulation | PDGFRB, STAT5B, JAK2 | KDR 10/4885KIT 31/4885PDGFRA 5/4885 |
| US-20170239255-A1 | Combination | PAICS, NUP205, CA5B | KDR 3766/4885KIT 2505/4885PDGFRA 1684/4885 |
| US-20180360971-A1 | PAZOPANIB FORMULATION | PDGFRB, STAT5B, JAK2 | KDR 10/4885KIT 31/4885PDGFRA 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.